Glaukos completes patient enrolment in Phase II trial of GLK-321
Summary
Glaukos completed patient enrollment in its Phase II trial of GLK-321 for Demodex blepharitis. The study includes 275 randomized patients across U.S. clinical sites and will test safety, tolerability, and efficacy at three dose levels. Glaukos is delivering the therapy through its iLution platform, a cream-based transdermal approach for eyelid treatment. The company says the program supports its broader ocular surface disease pipeline and targets a large underserved market.
Classifications
industries
HealthTech
applications
No applications detected
AI Classifications
Labels
Medical Software
Healthcare Technology
Ophthalmic Medical Devices
Linked Companies
Glaukos
$100M to $250M